International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2022): 7.942

Solid Lipid Nanoparticles: A Promising Drug Delivery System

Jugendra Singh[1], Shruti Khare[2]

Advance Institute of Biotech &P.M. Sciences, Naramau, Kanpur, Uttar Pradesh

Abstract: ***SLNs have been at the frontline of nanoscale and have a wide range of therapeutic uses in both research and medicine delivery. Lipid nanoparticles hold the potential for novel therapies due to their distinct size-dependent characteristics. The creation of a brand-new drug delivery prototype is made possible by the capacity to put medications into nano carriers. a potential target-specific medication delivery mechanism As a result, many scientists think that solid lipid nanoparticles have a lot of potential for obtaining precise and regulated medication administration. Numerous subjects are covered in this review. treatment of solid lipid nanoparticles: objectives, production steps, advantages, drawbacks, and prospective applications remedies Scanner electron microscopy and photon correlation spectroscopy are two analytical methods used to describe SLNs. additional methods, such as transmission electron and analysis. Lipids have distinct size-dependent characteristics that make them Weemphasise the advantages of differential scanning calorimetry. The in vivo destiny of the carriers and several aspects of the SLN delivery method are also covered.***

Keywords: Homogenization, TEM, PCS, and biodistribution targeting are all terms used to describe colloidal drug carriers

1. Introduction

Since its invention in 1990,(SLNs) have been exploited as an alternative to conventional colloidal carriers such emulsions, liposomes, and polymeric micro- and nanoparticles1. As a novel colloidal drug carrier for intravenous applications and an alternate particulate carrier system, nanoparticle consisting of solid lipids are becoming more and more popular. A physiological lipid dispersed in water or an aqueous detergent solution makes up SLNs, sub-micron colloidal carriers with sizes ranging from 0.5 to 1 µm. Due to their distinct characteristics, including their tiny size, large surface area, high drug loading, and phase interaction at the interface, SLN are interesting because they have the potential to enhance pharmacological performance.[2,5,6]

To over The phrases homogenization, TEM, PCS, and biodistribution targeting all refer to explain colloidal drug delivery systems. Due to the drawbacks of the liquid state of the oil droplets, the liquid was replaced by a solid lipid, which subsequently turned into solid lipid nanoparticles. Numerous factors contribute to the increased interest in lipid-based systems.

1) Lipids increase oral bioavailability while decreasing plasma profile variability.
2) Improved lipoid excipient characterisation.
3) Increased able to manage important problems such as technical assistance and manufacturing magnitude.

Microparticles are one of the only feasible colloidal carrier systems, acting similarly to an oil-in-water emulsion for parenteral feeding as an alternative to polymers. The solid lipid has been substituted for the liquid in the emulsion, as seen in Figure 1. They offer a variety of advantages, given the system's physical stability, low toxicity, superior biocompatibility, and the potential of solid lipid nanoparticles to more efficiently transport lipophilic drugs.



Figure 1: Shows the of The Graphical of SLNs



Figure 2: A graphical depiction of SLN on liposomes and emulsions

SLNs have been around since the early 1990 proven to colloidal carriers based on lipids. This is one of greatest effective the most widely used methods for increasing the oral bioavailability of drugs that are insoluble in water. SLNs are composed of physiologically tolerated lipid components that are solid at room temperature and have a submicron size range of 50-1000 nm. Figure 2 depicts a schematic representation of different particulate drug carriers, such as emulsions and liposomes, as well as their advantages over SLNs. Polymeric nanoparticles, fat emulsions, and liposomes are all combined in SLNs.

Benefits of SLNs

- Controlling and directing the release of drugs
- Outstanding biocompatibility.
- Boost pharmaceutical stability
- Simple to clean and sterilise
- Improved command of encapsulated compound Kinetics of release
- Significantly increased drug content
- A rise in the bioavailability of the bioactive substances trapped.
- More easily produced than biopolymeric nanoparticles; chemical protection of included labile chemicals; and lower production costs.
- There's no need for a specialized solvent.
- The production process for emulsions follows standard procedures.
- Similar raw ingredients to those used in emulsions are needed.
- Exceptionally high level of long-term stability.

Adaptability of the application

- Commercial sterilization procedures are possible.
- Simple to scale and sterilizer.
- Greater control over the kinetics of encapsulated compound release.
- Enhanced bioavailability of bioactives compounds entangled.

SLNs[4,6] Disadvantages

- Particle formation.
- An unpredictability in gelation.
- Polymeric transition dynamics that are unexpected.

The Purposes of Solid Lipid Nanoparticles [6,9].

- The ability to control drug release.
- Increased drug stability.
- Heavy drug payload.
- The carrier is not biotoxic.
- Avoiding solvents that are organic.
- Use drugs that are lipophilic and hydrophilic

2. Method of Fabrication of Solid Lipid Nanoparticles

1) Homogenization under more pressure.

- Heated environment homogenising
- Freezing and homogenising

2) More - speed homogenising and ultrasonification.

- ultrasonification of the probe
- ultrasonification of the bath.

3) The solvent evaporating.
4) Method of solvent emulsification-diffusion.
5) The subcritical water technique
6) Microemulsion - based approach
7) Using the squirt dryer technique
8) The two- emulsifiers technique
9) The type of precipitation
10) Ultrasonography's dispersion in films

A. Homogenization under high pressure (HPH)

For the manufacture of SLNs, it is a dependable and powerful technologyHigh-pressure homogenizers (100–2000 bar) push a liquid through a small opening (in the range of a few microns). In a very short span, The fluid speeds up from a really quite low velocity towordsa high speed (around 1000 kilometres/hour). Microbubble forces and hydrodynamic pressure strain cause the subatomic particles to be disturbed bottom to the sub - micron level . Although studies have looked at lipid contents up to 40%, the typical lipid percentage used is 5–10%.

Two popular HPH methods—heat environment, homogenising and freezing homogenising - both work by combining the medication with a significant amount of lipid melt.

I. Heated environment homogenization

Heated environment homogenization, which is also referred to as emulsion Uniformity occurs at temperatures above the lipid's melting point. Its drug-loaded fatty acid melt is vigorously mixed with the water - soluble emulsifier phase to shape a which was before. (at its same temperature). Relevant parameters of such which was before is performed at temperature increases above the lipid's melting. Smaller particle dimensions arise from the inner phase's viscosity decreasing at higher temperatures. On the other hand, excessive heat expedite its deterioration such as both its medication o the transporter . Increases in equilibration force or cycle count frequently lead in relation towards an expansion in portion size because of the particles' tremendous kinetic energy.



Figure 3: Heat enviroment homogenization is used to create solid lipid nanoparticles

II. Freezing and Homogenising

The complexity of the nanoemulsion's crystallisation step, which results in multiple alterations and amazingly liquids, as well as during homogenized, drug dispersion into the aqueous phase and temperature-induced drug degradation are a some of its issues associated with hot homogenization that were addressed by the development of cold homogenization. A pre-suspension is created by cooling the lipids melting that contains medications, grinding the thick lipids into tiny particles, and dispersing those in a cool emulsifier of particle. After homogenising which was before, the lipid microparticles are leading to the transformation into SLNs gravitational force, which is powerful enough to occur at or below room temperature.



Figure 4: Freezing homogenization procedure for the creation of solid lipid nanoparticles

Advantages

- Low initial outlay of funds.
- At the laboratory scale, proved.

Disadvantages

- Energy-consuming process.
- Biomolecule degradation on a laboratory scale.
- Distributions with a polydisperse distribution.

B. High-speed homogenization and ultrasonication

Additionally, SLNs are made utilising high-speed homogenization or ultrasonication techniques. AAt lower particle sizes, a mixture of maintains a strong and greater homogeneity is necessary sizes.calability has not been tested.

Advantages

- Shear stress has diminished.

Disadvantage

- Metal pollution may be present.
- Physical instability, such as the development of particles while being stored.

C. The solvent evaporating

Solvent evaporation is another method for producing SLNs. After being in a water, dissolved -insolubleorganic cleaner, the lipophilic material isin a water phase mixed (e.g., cyclohexane). Lipid precipitates in aqueous media as the solvent evaporates, generating nanoparticles with a mean size of27 nanometersThe solution was emulsified in a water phase using highly pressurized homogeneity. By boiling the solvents at low pressure (55–65 millibars), the chemical solvent was evaporated from the emulsify.

Advantages.
- scaled
- Advanced technologies.
- Continual procedure.
- Commercial demonstration.

Disadvantages
- This is a very energy-intensive process.
- Distributions that are polydisperse.
- Biomolecule deterioration.

D. Method of emulsifying of solutions
Particle can range in size from 30 to 100 nanometer on averages. created using its method. The absence of The main benefit of the process is heat during preparation.



Figure 5: An illustration of the diffusion method for emulsification.

E. The subcritical water technique
Utilizing particles from gas-saturated liquids is a different method of creating SLNs (PGSS).

Advantages
Steer clear of solvents if at all possible

F. Microemulsion-based approach
Itstechnique makes use of Distillation of microspheres .Two-phase system comprises of an insides and an external phase. micro-emulsions, such as o/w microemulsions. In order to create them,an emulsifying agent, a lower melting point fatty acid (such as ethanoic acid), such co-emulsifiers (such as polysorbate 20) (such as propanol), as well as water are stirred together at a temperature between 65 and 70 degrees Celsius. In ice water (2-3°C), the warm nanoemulsion is diffused. while being stirred. To move solid products (tablets, pellets) throughthe granulation approach, the SLNs diffusion can be employed asa fluids for gelation, however,if the quantity of waterin the mixture is too high due to low particle concentration, Water must be extracted. High-temperature gradients promote lipid synthesis. aggregation or crystallisation quickly. The lipid contents that can be retrieved are much less as a result of the dilution procedure. Suspension in lieu of The resulting particles are apowdered sugar mild atmospheric pressure and temperature conditions The ideal solvent for this method is carbon dioxide solution.

The price is less expensive than formulations based on HPH. versus HPH-based formulations versus HPH-based formulations.



Figure 6: Using a microemulsion

Benefits
- Low mechanical energy input
- the system is theoretically stable.

Disadvantages
- Extremely susceptible to change.
- Formulation work that is time consuming.
- Nanoparticle concentrations are low.

G. Using the spray dryer method
It is a method that can be used instead of lyophilization. This suggests that using a lipid containing agreater than 70°C melting point is appropriate.With SLNs, the best results were obtained.concentrationsof one percent in a trehalose in water solution or 20% in an ethanol-water mixture.

H. The two-emulsion technique
In order to save medicinepart intoIn this case, its medicine is encased with a stabilizing agent in the the outside water phase of a w/o/w dual emulsification all through stabiliser.

I. The type of precipitation
After being chemical dispersed (like chloroform), its glyceridesin a water phase are homogenised Fatty acid would then water vapour. forming nanoparticleswhen the organic phase has been depleted disappeared.

J. Ultrasonography's dispersion in films
A lipid film was produced after the organic solutions were decompressed, rotated, and evaporated with the addition of the lipid and the medication in the appropriate organic solutions. The emulsions-containing aqueous solution was then added. Finally, utilising ultrasound with the From inquiry to diffuser, the SLNs with narrow and homogeneous particle diameter is produced. produced.

3. Conclusion

Contrary to widespread assumption, SLNsneedn't "merge the benefits of other flocculation dosage forms" while avoidintheir shortcomings." its finished product couldn't just and labelled solid-coreorder to further assist. The physiological components in the composition, the quick and efficient production method, which includes the capacity to produce large amounts, the ability to create airlines with enhanced entrapment efficiency, as well as the evasion of polar compounds are all unmistakable benefits of SLN. Drug encapsulation capabilities are lesser, as well as availability ofThe complexity of the lipid's physical state (transformation between different modifications), as well as the potential for super-cooled melts, are all drawbacks that affect stability during storage or administration (gelation, particle size increase, drug expulsion). a dissolved test of or When water is removed, the equilibria between different particulate organisms and the physiological state of the fatty acid are restored. may be significantly changed. The accurate characterization of complicated surfactant/lipid dispersions requires the employment of numerousIn addition to evaluating size of the particles, analysis techniques are used. Kinematics must be taken into consideration. Drug nanosuspensions will be able to coexist in the sample thanks to Spectroscopic, Elevated serum, and cyclotron radiation exposure. Unfortunately, these considerations are frequently overlooked, and the term "narcotic integration" in SLNs literature is frequently ambiguous.. In conclusion, as compared to other colloidal carriers, SLNs arehighly complex devices with the both clear advantages and disadvantages . Investigations conductedBoth in vitro or in vivo testing are still required.to fully comprehend its structure and dynamics of SLNs.

References

[1] S. Mukherjee, S. Ray and R.S.Thakur, Ind. J. Pharm.Sci., 349-358 (2009). 2. M.R.Mozafari, 41-50 (2006).
[2] Rainer H.Muller, Karsten Mader and Sven Gohla, Eur.J. Pharm.Biopharm., 50**(1)**, 161-177(2000).
[3] Wolfgang Mehnart and Karsten Mader, Adv. Drug. Deliv. Rev., **47**, 165-196(2001).
[4] HouliLi, Xiaobin Zhao, Yukun Ma and Guangxi Zhai, Ling Bing Li and Hong Xiang, Lou.J. Cont. Release, **133**, 238-244(2009).
[5] Melike Uner, Gulgun Yener, Int.J.Nanomedicine, **2(3)**, 289-300(2007).
[6] Annette Zur Mehlen, Cora Schwarzand Wolfgang Mehnart, Eur. J.Pharm. Biopharm., **45**, 149-155 (1998).
[7] ElenaUgazia, Roberta Cavalli and M.R.Gasco, Int. J. Pharm., **241**, 341-344(2002).
[8] Indu Pal Kaur, Rohit Bhandari, Swati Bhandari and Kakkur. J.Cont. Rel., **127**, 97-109(2008).
[9] Ghada Abdelbary and Rania H. Fahmy, AAPS Pharm. Sci.Tech., **10(1)** (2009).
[10] N.Al-Haj and A.Rasedee, Int.J. Pharmacol., **5(1)**, 90-93(2009).
[11] DongZhiHou, Chang Sheng Xie, Kaijn Huangand Chang Hong Zhu, Biomaterials, **24**, 1781-1785 (2003).
[12] Alessandro Bargoni, RobertoCavalla, Otto Caputo and M.RGasco, Pharm.Res., **15**(**5)**, 745-750(1998).
[13] Milan Stuchlík and StanislavŽák, Biomed, Papers, **145 (2)**, 17-26(2001).
[14] C.O lbrich and R. H. Muller, Int. J. Pharm., **180**, 31-39 (1999).
[15] D.Schwarz, W.Mehnert, J.S.LucksandR.H.Muller, J.Cont.Release, **30**, 83-96(1994).
[16] WeiLiu, MelingHu, Wehsuang Liuand ChengbinXue, HuibiXu, Int.J.Pharm., **364**, 141-146(2008).
[17] QingZhiLu, AihuaYu, YanweiXiandHouliLi, ZhimeiSong, JingCuiandFengliangCao, GuangxiZhai, Int.J.Pharm., **372**, 191–198(2009).
[18] YiFanLuo, DaWeiChen, LiXiangRenandXiuLiZhao, JingQin, J.Cont.Release, **114**, 53–59(2006).
[19] RishiPaliwal, ShivaniRai, Bhuvaneshwar Vaidya, KapilKhatri, AmitK.Goyal, NeerajMishra, Abhinav Mehta and SureshP.Vyas, PhD.Nanomedicine, Nanotechnology, Biology and Medicine, **5(2)**, (2009) pp.184-191.
[20] Zhenghong Xu, LingliChen, Wangwen Guand Yu Gao, LipingLin, Zhiwen ZhangandYongXi, YapingLi, Biomaterials, **30**, 226(2009).
[21] Rathapon Asasutjarit, Sven-IverLorenzen, Sunee Sirivichayakul and Kiat Ruxrungtham, Uracha Ruktanonchi and GarnpimolC.Ritthidej, Pharm.Res., **24(6)**, 1098–1107(2007).
[22] CarstenRudolph, UlrikeSchillinger, Aurora Ortizand Kerstin Tabatt, Christian Plank, Rainer H. Müller and Joseph Rosenecker, Pharm.Research, **21(9)**, 1662-1669(2004).
[23] Robhash Kusam Subedia, KeonWookKangaandHoo-Kyun Choi, Eur.J.Pharm.Sci., **37(3-4)**, 508-513 (2009).
[24] SureshGande, Kopparam Manjunath, Vobalaboina Venkateswarlu and Vemula Satyanarayana, AAPS Pharm.Sci.Tech., **8(1)**, Article24(2007).
[25] NagiA.Alhaj, Rasedee Abdullah, Siddig Ibrahim and Ahmed Bustamenn, Amer. J. Pharmacology and Toxicology, **3(3)**, 219–224(2008).
[26] Michael D.Triplett, E.James, F.Rathman, J. Nanopart Res., **11**, 601–614(2009).
[27] Yung-Chih Kuoand Hung-HaoChen, Int.J.Pharm., **365**, 206-213(2009).
[28] K.Vivek, Harivardhan Reddyand Ramachandra S. R. Murthy, AAPS Pharm. Sci.Tech., **8(4)**, Article 83(2007).
[29] S.Mukherjee, Subhabrata Ray and R.S.Thakur,

Pak.J.Pharm.Sci., **22(2)**, 131-138(2009).
[30] E.Q.Hu, H.Yuan, H. H .Zhang and M.Fang, Int. J. Pharm., **239**, 121-128(2002).
[31] Niladi Chattopadhyay, JasonZastre, Ho-Lun Wongand Xiao Yu Wu, ReinaBendayan, Pharm. Research, **25(10)**, (2008).
[32] KatjaJores, Annekathrin Haberland, Siegfried Wartewigand Karsten Mader, Wolfgang Mehnart, Pharm.Res., **22(11)**, 1887-1879(2005).
[33] BinLua, Su-BinXionga, HongYangaandXiao-DongYina, Ruo-Bing Chaoa, Eur. J. Pharmaceutical Sci., **28(1-2)**, 86- 95(2006).
[34] Meyer E Heinzelmann and Wiesendanger R. Springer Verlogg, 99-149(1992).
[35] Pallav iV. Pople and KamalinderK.Singh, AAPS Pharm.Sci.Tech., **7(4)**, Article91(2006).
[36] Lang Sc, LuL.F, Cai Yand Zhu J.B, Liang BW and Yang CZ, J. Controlled Release, **59**, 299-307(1999).
[37] Biswajit Basu, KevinGarala, Ravi Bhalodia and Bhavik Joshi, Kuldeep Mehta, J.Pharm.Res., **3(1),** 84-92(2010).
[38] Wolfgang Mehnert and KarstenMader, Adv. Drug Delivery Rev., **47**, 165-196(2001).
[39] Vivek RanjanSinha, Saurabh Srivastava and Honey Goel, Int.J.Adv.Pharm.Sci., **1**, 212-238(2010).
[40] Melike Uner, GulgunYener, Int. J. Nanomedicine, **2(3)**, 289-300(2007).
[41] KarstenMader, 187-212.
[42] Antonio J. Almeida and Eliana Souto, Adv.Drug Delivery Rev., **59**, 478-490(2007).
[43] Manisha Misra, P.Muthuprasanna and K. Surya Prabha, Int.J.Pharm.Tech.Res., **1(4)**, 1354-1365 (2009).
[44] MalgorzataSmola, Thierry Vandamme and Adam Sokolowski, Int.J.Nanomedicine, 1-9(2008).
[45] Jessy Shajiand VinayJain, Int.J.Pharmacy and Pharm. Sci., **2(3)**, 8-17(2010).
[46] Biswajit Basu, Kevin Garala, Ravi Bhalodia and Bhavik Joshi, Kuldeep Mehta, J.Pharm.Res., **3(1)**, 84-92(2008).
[47] Suphiya Pareev and Sanjeeh K.Sahoo, Nanomedicine, Nanotechnology, Biology and Medicine, xx.xxx-xxx (2011).
[48] S.Mukherjee, S. Ray and R.S.Thakur, Ind J. Pharm.Sci., 349-358(2009).
[49] HaniaDegobert, Adv. Drug Delivery Reviews, 1688-1713(2006).